Aripiprazole CAS 129722-12-9 Puritas >99.0% (HPLC) API
Manufacturer Supple intermedia Aripiprazole Cum High puritate
Aripiprazole API CAS 129722-12-9
1-(2,3-Dichlorophenyl) piperazinum hydrochloridum CAS 119532-26-2
7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone CAS 22246-18-0
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone CAS 129722-34-5
| Nomen chemicum | Aripiprazole |
| Synonyma | 7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]butoxylum]-3,4-Dihydro-2(1H)-Quinolinone |
| CAS Number | 129722-12-9 |
| CATTUS Number | RF-PI2270 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C23H27Cl2N3O2 |
| M. Pondus | 448.39 |
| Solubilitas | Solubile in aqua solutum;Insolubilis in Methanolum |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba aut fere alba Crystallina pulveris |
| Lepidium sativum | per IR;per HPLC |
| Solubilitas | Solutum in Acidum aceticum, leviter solutum in Ethanol |
| Liquescens punctum | 136.0~140.0℃ |
| Damnum in Siccatio | <0.50% |
| Residere in Ignition | <0.10% |
| Metalla gravis | ≤20ppm |
| RELICTUM Solvents | |
| Ethanol | ≤1000ppm |
| DMF | ≤200ppm |
| Substantiae cognatae | |
| Unam immunditiam | <0.20% |
| Totalis immunditias | <1.00% |
| Puritas / Analysis Methodus | >99.0% (HPLC) |
| Assay | 98.0%~ 102.0% (ex Anhydrous Basis) |
| Micro limites | |
| Summa Aerobic Microbial comitis | ≤1000 cfu/g* |
| Fermentum et fingunt Combinatae quaevis | ≤100 cfu/g* |
| E·Coli | absentia |
| Organising morbificae | absentia |
| Test Standard | Enterprise Standard |
| Consuetudinem | API;Antipsychotic |
sarcina: Utrem, 5kg/aluminium stannum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
Aripiprazole (CAS: 129722-12-9) novum genus derivatorum quinolineorum solubilium valde lipidorum, eius effectus pharmacologicus proprius est quod non solum dopamine postsynaptico D2 receptor adversario, sed etiam dopamine presynaptico D2 receptor agonist, potest etiam. receptores D1, D3, D4 receptores.Aripiprazole est secunda generatio atypica antipsychotica et anti-depressans cum actione agonista partialis in dopamine D2 et receptoribus serotonin 5-HT1A et actuositatis antagonista in receptoribus serotonin 5-HT2A.Valores Ki sunt 0.34 nM, 0.8 nM, 1.7 nM, 3.4 nM, respective pro dopamine D2 et D3, serotonin 5-HT1A et 5-HT2A receptores.Aripiprazole ad curationem schizophreniae et perturbationes psychoticas pertinentes adhibetur.Bristol-Myers Squibb et Otsuka pharmaceutica Societas nuntiavit Unionem Europaeam Abilify (Aripiprazole) in curatione schizophreniae enumeratis applicationis approbasse.Schizophrenia 1% incolarum globalis afficit et magis in iuvenibus adultis.SCHIZOPHRENIA afficit cogitandi, motus animique moderandi ac decernendi facultatem patientis.Aegri Schizophrenia-positivi symptomata habebunt sicut hallucinationes et deceptiones, aegros negativa symptomata sunt recessus socialis, defectus motus mutationum.Anno 2002 FDA approbavit Facultatem ad tractationem schizophreniae, quae quinque vires dosis habet: 5 mg, 10 mg, 15 mg, 20 mg et 30 mg, cum approbatione.
